Table 2.
Differences between patients with fibrillary glomerulonephritis based on race and hepatitis C virus status at UNC Kidney Center
| UNC Kidney Center (n = 42) |
Black (n = 11) |
White (n = 30) |
p value | HCV (–) (n = 19) |
HCV (+) (n = 7) |
p value† | |
|---|---|---|---|---|---|---|---|
| Demographics | |||||||
| Age, years | 54±11 | 49±8 | 56±11 | 0.06 | 58±12 | 50±3 | 0.02 |
| Female, % | 60 | 46 | 63 | 0.49 | 63 | 29 | 0.19 |
| Black race, % | 26 | – | – | 16 | 100 | <0.001 | |
| Laboratory values | |||||||
| Serum creatinine, mg/dL | 3.2±4 (38) | 4.7±4 | 2.7±4 (26) | 0.01 | 3.4±4 | 2.9±0.9 | 0.31 |
| eGFR, mL/min/1.732 | 35±20 (38) | 25±17 | 36±23 (25) | 0.11 | 31±20 | 29.5±15 | 0.96 |
| Albumin, g/dL | 3.1±1 (24) | 2.8±0.9 | 3.5±0.8 (12) | 0.08 | 3.2±0.9 (13) | 2.9±1 | 0.66 |
| Proteinuria, g/24 h | 5.7±5 (33) | 7.0±4.6 (9) | 5.5±4.8 (24) | 0.24 | 7.0±5 (18) | 6.4±5 (6) | 0.97 |
| Proteinuria (any) | 95 (36) | 100 (11) | 96 (24) | 1 | 100 | 100 (6) | 1 |
| Hematuria (any) | 97 (37) | 100 (11) | 92 (25) | 1 | 100 | 100 (6) | 1 |
| BUN, mg/dL | 36±19 (29) | 44±20 (10) | 33±16 (18) | 0.11 | 38±18 (17) | 42±20 | 0.57 |
| Cholesterol, mg/dL | 220±87 (13) | 212±93 (6) | 238±90 (7) | 0.73 | 254±81 (7) | 202±100 (5) | 0.43 |
| HDL, mg/dL | 59±24 (10) | 68±30 (5) | 44±16 (5) | 0.17 | 44±17 (5) | 71±34 (4) | 0.27 |
| LDL, mg/dL | 133±50 (10) | 137±40 (5) | 109±76 (5) | 0.31 | 126±77 (5) | 130±43 (4) | 0.91 |
| TG, mg/dL | 186±106 (9) | 164±111 (5) | 428±425 (4) | 0.29 | 457±397 (4) | 155±127 (4) | 0.11 |
| Systolic BP, mm Hg | 141±19 (34) | 144±23 | 140±18 (22) | 0.86 | 143±20 (18) | 140±21 | 0.63 |
| Diastolic BP, mm Hg | 82±11 (34) | 86±12 | 80±10 (22) | 0.13 | 79±12 (18) | 84±8 | 0.35 |
| WBC, 109/L | 7.4±3 (21) | 7.5±2.8 (9) | 6.8±2.3 (11) | 0.82 | 6.9±3 (12) | 7.4±2.5 | 0.90 |
| HCT, % | 31±8 (19) | 30±9 (8) | 32±7 (10) | 0.97 | 30±9 (12) | 34±5.5 (6) | 0.37 |
| Hemoglobin, g/dL | 10.9±2 (23) | 10.6±1.4 (10) | 11.2±2.5 (12) | 0.74 | 10.6±2.2 (14) | 11±2.5 | 0.39 |
| Platelets, 109/L | 256±95 (22) | 251±105 (10) | 262±96 (11) | 0.81 | 240±112 (12) | 275±86 | 0.64 |
| ANA, % (n) | 41 (29) | 40 (10) | 42 (19) | 1 | 42 | 50 (6) | 1 |
| C3, mg/dL | 113±29 (17) | 102±11 (6) | 124±37 (11) | 0.07 | 122±36 (12) | 101±12 (5) | 0.14 |
| C4, mg/dL | 30±9 (17) | 33±9 (6) | 29±10 (11) | 0.72 | 28±10 (12) | 35±8 (5) | 0.32 |
| Hypocomplementemia, % (n) | 9 (23) | 13 (8) | 7 (15) | 1 | 7 (15) | 50 (2) | 0.23 |
| Serum immunofixation, % (n) | 42 (19) | 17 (6) | 54 (13) | 0.33 | 54 (11) | 25 (4) | 0.58 |
| SPEP, % (n) | 41 (22) | 17 (6) | 47 (15) | 0.34 | 46 (13) | 25 (4) | 1 |
| UPEP, % (n) | 20 (10) | 33 (3) | 14 (7) | 1 | 20 (5) | 50 (2) | 1 |
| Hepatitis B, % (n) | 8 (26) | 20 (10) | 0 (16) | 0.14 | 0 (17) | 29 | 0.07 |
| Hepatitis C, % (n) | 27 (26) | 70 (10) | 0 (16) | <0.001 | 0 | 100 | <0.001 |
| HIV, % (n) | 5 (19) | 11 (9) | 0 (10) | 0.47 | 8 (12) | 0 | 1 |
| Comorbidities, % (n) | |||||||
| Malignancy | 15 (40) | 10 (10) | 17 (29) | 1 | 16 | 14 | 1 |
| COPD | 13 (40) | 30 (10) | 7 (29) | 0.10 | 11 | 43 | 0.10 |
| CAD | 20 (40) | 10 (10) | 24 (29) | 0.65 | 26 | 14 | 0.65 |
| AI | 13 (40) | 20 (10) | 10 (29) | 0.59 | 21 | 0 | 0.55 |
| DM | 28 (40) | 30 (10) | 24 (29) | 0.69 | 16 | 43 | 0.30 |
| Outcomes, % | |||||||
| Dialysis | 36 | 82 | 30 | 0.004 | 26 | 89 | 0.02 |
| Transplant | 10 | 0 | 13 | 0.56 | 6 | 0 | 1 |
| Death | 24 | 36 | 20 | 0.41 | 21 | 43 | 0.34 |
Mean ± SD, (n) given if less than n in header row, bolded p value denotes significance.
Fisher’s exact test for categorical variables (%), Mann–Whitney test for continuous variables.
eGFR calculated using MDRD equation, other or unreported race n = 1 data not shown.
GFR, glomerular filtration rate; BUN, blood urea nitrogen; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; BP, blood pressure; WBC, white blood cell; HCT, hematocrit; ANA, anti-nuclear antibody; C in C3/4, complement; SPEP, serum protein electrophoresis; UPEP, urine protein electrophoresis; SLC, serum light chain; HIV, human immunodeficiency virus; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; AI, autoimmune disease; DM, diabetes mellitus.